Anti-PD-1 therapy
Anti-PD-1 therapy is a class of cancer immunotherapy in which monoclonal antibodies — nivolumab and pembrolizumab among them — block the Programmed cell death 1 (PD-1) receptor on T cells, interrupting its engagement by the ligand CD274 molecule.
Anti-PD-1 therapy is a class of cancer immunotherapy in which monoclonal antibodies — nivolumab and pembrolizumab among them — block the Programmed cell death 1 (PD-1) receptor on T cells, interrupting its engagement by the ligand CD274 molecule. PD-1 is an inhibitory checkpoint that normally restrains T-cell activation to limit autoimmunity, and many tumors exploit it to escape attack; blocking PD-1/PD-L1 signaling restores cytotoxic effector function in T cells that have already recognized the tumor. This is the crucial condition — the drugs release a brake rather than supply a signal, so they work only where tumor-reactive T cells are present. Anti-PD-1 belongs to the broader checkpoint inhibitor family alongside anti-PD-L1 antibodies and blockade of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and is used across many solid tumors including melanoma, hepatocellular carcinoma and cervical cancer, as well as in the tissue-agnostic setting of mismatch repair–deficient or microsatellite instability–high disease, where the indication follows a molecular feature rather than an organ.
Because the mechanism is release of a physiological restraint, the characteristic toxicities are immune-related adverse events — colitis, hepatitis, pneumonitis, dermatitis and endocrinopathies affecting the pituitary, thyroid and adrenal axes. Their management inverts the therapeutic logic, requiring corticosteroids or further immunosuppression, and endocrine damage is often permanent even when the inflammation resolves.
Response depends heavily on the tumor microenvironment. Tumors that respond tend to carry pre-existing CD8+ T-cell infiltrates and active interferon gamma signaling, while resistance is associated with T-cell exhaustion, immunosuppressive macrophage and myeloid states, cancer-associated fibroblasts including fibroblast activation protein alpha (FAP)-positive populations, and tumor-derived extracellular vesicles that propagate suppression. Alternative checkpoints such as TIGIT with its ligand CD155 can sustain inhibition even when PD-1 is blocked, and loss of interferon signaling or of antigen presentation removes the pathway the drug depends on. Current work therefore centers on converting immunologically cold tumors into responsive ones, through combinations and through mechanisms spanning CD28 costimulatory signaling that supports T-cell activation, Spp1-mediated myeloid recruitment, proprotein convertase subtilisin/kexin type 9 (PCSK9), Sting-dependent innate sensing, oncolytic viruses and tumor metabolic pathways such as fatty acid uptake.
Where the papers sit
21 papers from the last 6 months study Anti-PD-1 therapy directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 4 observational · 4 human data · 8 preclinical · 5 unclassified
Themes 4 themes
-
Immune Resistance Mechanisms
Tumor immune resistance is increasingly traced to suppressive myeloid niches, altered metabolism and dysfunctional CD8-positive T cells. NNMT, ALDH9A1-carnitine signaling, SPP1, PD-L1/mTOR regulation and ferroptosis-resistant myeloid cells recur as actionable mechanisms. PET tracking and single-cell multiomics are sharpening response assessment. In situ vaccination and pathway-targeted combinations aim to restore anti-PD-1 sensitivity.
8 papers · 38.1%
-
Metabolic Resistance in HCC
Anti-PD-1 resistance in hepatocellular carcinoma is being framed as a metabolic and microenvironmental problem. ChREBP/PKLR-driven lactate, lipid abnormalities and mast-cell CCL17/CCR4 signaling can suppress cytotoxic T-cell activity. Extracellular vesicles and tumor-selective CD28 siRNA lipid nanoparticles are being targeted to remodel these barriers. Multimodal profiling of neoadjuvant nivolumab aims to identify combinations that overcome resistance.
6 papers · 28.6%
-
Checkpoint Therapy and Tregs
Checkpoint treatment is moving toward perioperative combinations and direct control of regulatory T cells. Neoadjuvant PD-1 blockade with oncolytic virus shows durable benefit in acral melanoma, while STING signaling remains linked to resistance. IKZF2/IKZF4 degraders offer a pharmacologic route to weaken Treg programs. Clinical studies also expose trade-offs, including increased opioid use after surgery and variable adjuvant survival outcomes.
4 papers · 19%
-
Others — PD-1 Toxicity and Tumor Escape
PD-1 treatment produces both endocrine toxicity and tumor immune escape, but this cluster has no single direction. Pituitary-axis dysfunction and broader immune-related adverse events are being characterized through proteomic and metabolomic changes. Lipid, tryptophan and SNRPA-associated signals appear among candidate biomarkers. Separately, CD155 links cervical-cancer immunotype to epithelial-directed therapy beyond checkpoint blockade.
3 papers · 14.3%
Papers
The 21 papers from the last 6 months that study Anti-PD-1 therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Immune Resistance Mechanisms (8)
- Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
- [68Ga]Ga-NODAGA-SNA006 PET/CT Reveals CD8+ T-Cell Dynamics in Lung Cancer Progression and Anti-PD-1 Response. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 27 Aug 2026 PMID 42660635
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 10 Aug 2026 PMID 42574617
- A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
- Ferroptosis-resistant myeloid niche shapes tumor natural evolution in glioblastoma. Cancer letters · 9 Jul 2026 PMID 42425190
- Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment. Oncogene · 17 Jun 2026 PMID 42310095
- Exosomal circFXR1 drives immune evasion and tumor progression through dual regulation of PD-L1 and mTOR signaling in gastric cancer. Cancer letters · 30 May 2026 PMID 42217559
- PD1+ TIGIT+ CD4+ T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis. RMD open · 20 May 2026 PMID 42161414
Metabolic Resistance in HCC (6)
- Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment. Journal of biochemical and molecular toxicology · 20 Oct 2026 PMID 42900017
- Targeting the ChREBP/PKLR-lactate axis via Huachansu tablets restores CD8⁺T cell immunity in MASH-HCC. Pharmacological research · 14 Sept 2026 PMID 42735733
- Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer. Annals of medicine · 25 Aug 2026 PMID 42638413
- Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261788
- Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma. Molecular cancer · 2 Jun 2026 PMID 42226281
- Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides. Signal transduction and targeted therapy · 27 May 2026 PMID 42204141
Checkpoint Therapy and Tregs (4)
- Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors. Journal of medicinal chemistry · 1 Sept 2026 PMID 42677819
- When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction. Breast cancer research and treatment · 12 Aug 2026 PMID 42584510
- Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). European journal of cancer (Oxford, England : 1990) · 29 Jun 2026 PMID 42372635
- Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy. Experimental hematology & oncology · 2 Jun 2026 PMID 42226303
Others — PD-1 Toxicity and Tumor Escape (3)
- Proteomic and Metabolomic Analysis of Immune-Related Adverse Events in Patients Treated with PD-1 Inhibitors. Journal of proteome research · 4 Sept 2026 PMID 42695906
- Multiple endocrine adverse reactions and pituitary axis dysfunction induced by PD-1 immunotherapy in an esophageal cancer patient: Case report. Medicine · 23 May 2026 PMID 42175425
- CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer. Journal for immunotherapy of cancer · 20 May 2026 PMID 42161400
By study type
Observational studies and case reports (4)
- Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer. Annals of medicine · 25 Aug 2026 PMID 42638413
- When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction. Breast cancer research and treatment · 12 Aug 2026 PMID 42584510
- Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). European journal of cancer (Oxford, England : 1990) · 29 Jun 2026 PMID 42372635
- Multiple endocrine adverse reactions and pituitary axis dysfunction induced by PD-1 immunotherapy in an esophageal cancer patient: Case report. Medicine · 23 May 2026 PMID 42175425
Human data, design not indexed (4)
- Proteomic and Metabolomic Analysis of Immune-Related Adverse Events in Patients Treated with PD-1 Inhibitors. Journal of proteome research · 4 Sept 2026 PMID 42695906
- [68Ga]Ga-NODAGA-SNA006 PET/CT Reveals CD8+ T-Cell Dynamics in Lung Cancer Progression and Anti-PD-1 Response. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 27 Aug 2026 PMID 42660635
- PD1+ TIGIT+ CD4+ T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis. RMD open · 20 May 2026 PMID 42161414
- CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer. Journal for immunotherapy of cancer · 20 May 2026 PMID 42161400
Preclinical: animal, cell and lab studies (8)
- Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment. Journal of biochemical and molecular toxicology · 20 Oct 2026 PMID 42900017
- Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
- Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors. Journal of medicinal chemistry · 1 Sept 2026 PMID 42677819
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 10 Aug 2026 PMID 42574617
- A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
- Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment. Oncogene · 17 Jun 2026 PMID 42310095
- Exosomal circFXR1 drives immune evasion and tumor progression through dual regulation of PD-L1 and mTOR signaling in gastric cancer. Cancer letters · 30 May 2026 PMID 42217559
- Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides. Signal transduction and targeted therapy · 27 May 2026 PMID 42204141
Unclassified: not yet indexed with MeSH (5)
- Targeting the ChREBP/PKLR-lactate axis via Huachansu tablets restores CD8⁺T cell immunity in MASH-HCC. Pharmacological research · 14 Sept 2026 PMID 42735733
- Ferroptosis-resistant myeloid niche shapes tumor natural evolution in glioblastoma. Cancer letters · 9 Jul 2026 PMID 42425190
- Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261788
- Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy. Experimental hematology & oncology · 2 Jun 2026 PMID 42226303
- Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma. Molecular cancer · 2 Jun 2026 PMID 42226281
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-09-16 by GPT. Corrections: 2026-08-08 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.